Teva Pharmaceutical Industries Ltd. has been a standout performer in the Medical sector this year, surpassing its peers. It currently holds a strong position among its competitors, as indicated by its Zacks Sector Rank of #2.
Teva has returned an impressive 76.1% year-to-date, outperforming the average gain of 6.6% for Medical stocks overall. Analysts have shown increased confidence in the company, with a 0.6% upward revision in the Zacks Consensus Estimate for TEVA's full-year earnings over the past 90 days.
Teva operates within the Medical - Generic Drugs industry, which ranks #82 in the Zacks Industry Rank. The industry has gained about 19.2% year-to-date.
Addus HomeCare, another notable player in the Medical sector, has also demonstrated strong performance, returning 40.1% since the beginning of the year. Addus operates within the Medical - Outpatient and Home Healthcare industry, which is currently ranked #28. The industry has seen an 18% increase year-to-date.
Teva and Addus are both expected to continue delivering solid returns due to favorable market conditions and strong operational fundamentals. Teva's strong earnings outlook and positive analyst sentiment position it well for sustained growth.